Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.57 |
| ▸ | ESR1 | P03372 | 1/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 4/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.48 |
| ▸ | TYR | P14679 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ALOX15B | O15296 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29869998 | 1.00 | TTR (0.57) | TTRESR1ESR2ALOX15ALOX12 | |
| SCHEMBL29114658 | 1.00 | TTR (0.57) | TTRESR1ESR2ALOX15ALOX12 | |
| SCHEMBL30205823 | 1.00 | TTR (0.57) | TTRESR1ESR2ALOX15ALOX12 | |
| SCHEMBL31643797 | 1.00 | TTR (0.57) | TTRESR1ESR2ALOX15ALOX12 | |
| SCHEMBL1850123 | 1.00 | TTR (0.57) | TTRESR1ESR2ALOX15ALOX12 | |
| SCHEMBL29369381 | 0.96 | ALOX15 (0.55) | TTRESR1ESR2ALOX15ALOX12 | |
| SCHEMBL29724948 | 0.95 | ALOX15 (0.59) | TTRESR1ESR2ALOX15ALOX12 | |
| SCHEMBL28770238 | 0.95 | ALOX15 (0.59) | TTRESR1ESR2ALOX15ALOX12 | |
| SCHEMBL31544871 | 0.90 | TTR (0.54) | TTRESR1ESR2ALOX15ALOX12 | |
| SCHEMBL29737518 | 0.90 | TTR (0.54) | TTRESR1ESR2ALOX15ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296717-B2 | Synthesis of C-3 coupled biflavonoids and C-3 coupled biflavonoid analogues | UNIVERSITY OF THE FREE STATE (ZA) | 2016-03-29 | — | — | US | disclosed |
| US-9296717-B2 | Synthesis of C-3 coupled biflavonoids and C-3 coupled biflavonoid analogues | UNIVERSITY OF THE FREE STATE (ZA) | 2016-03-29 | — | — | US | disclosed |
| US-20120289715-A1 | Synthesis of C-3 Coupled Biflavonoids and C-3 Coupled Biflavonoid Analogues | UNIVERSITY OF THE FREE STATE (ZA) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289715-A1 | Synthesis of C-3 Coupled Biflavonoids and C-3 Coupled Biflavonoid Analogues | CBR3, C9, PROC | TTR 2573/4885ESR1 2116/4885ESR2 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.